nervous system, London: Her Majesty’s Stationary Of-
fice; 1981.
17. Bohannon RW, Smith MB. Interrater reliability of a modi-
fied Ashworth scale of muscle spasticity. Phys Ther 1987;
67: 206–207.
18. Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Mea-
suring balance in the elderly: validation of an instrument.
Can J Public Health 1992; 83 Suppl 2: S7–S11.
19. Podsiadlo D, Richardson S. The timed “Up & Go”: a test
of basic functional mobility for frail elderly persons. J Am
Geriatr Soc 1991; 39: 142–148.
20. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM.
Two-, six-, and 12-minute walking tests in respiratory
disease. Br Med J (Clin Res Ed) 1982; 284: 1607–1608.
21. Powell LE, Myers AM. The Activities-specific Balance Con-
fidence (ABC) Scale. J Gerontol A Biol Sci Med Sci 1995;
50A: M28–M34.
22. Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal
KR, Simpson DM, et al. Evidence–based review and as-
441
sessment of botulinum neurotoxin for the treatment of
adult spasticity in the upper motor neuron syndrome.
Toxicon 2013; 67: 115–128.
23. Takenaga S, Kawahigashi Y, Sonoda Y, Horikiri T, Hirata K,
Arimura K, et al. [Treatment of spastic paraparesis with bo-
tulinum toxin with reference to beneficial effects, disease
severity and long–term treatment.] Rinsho Shinkeigaku
1995; 35: 251–255 (in Japanese).
24. Klebe S, Stolze H, Kopper F, Lorenz D, Wenzelburger R,
Volkmann J, et al. Gait analysis of sporadic and hereditary
spastic paraplegia. J Neurol 2004; 251: 571–578.
25. Ellis RG, Sumner BJ, Kram R. Muscle contributions to pro-
pulsion and braking during walking and running: insight
from external force perturbations. Gait Posture 2014;
40: 594–599.
26. Nonnekes J, de Niet M, Oude Nijhuis LB, de Bot ST, van de
Warrenburg BP, Bloem BR, et al. Mechanisms of postural
instability in hereditary spastic paraplegia. J Neurol 2013;
260: 2387–2395.
Functional effects of botulinum toxin in patients with HSP
J Rehabil Med 51, 2019